Wellington Management Group LLP Sells 620,611 Shares of Agios Pharmaceuticals, Inc. $AGIO

Wellington Management Group LLP trimmed its stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 96.7% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 20,875 shares of the biopharmaceutical company’s stock after selling 620,611 shares during the quarter. Wellington Management Group LLP’s holdings in Agios Pharmaceuticals were worth $775,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in AGIO. BlackRock Inc. acquired a new stake in Agios Pharmaceuticals in the second quarter valued at approximately $239,582,000. Bellevue Group AG increased its holdings in shares of Agios Pharmaceuticals by 3.5% during the third quarter. Bellevue Group AG now owns 3,714,736 shares of the biopharmaceutical company’s stock worth $149,110,000 after buying an additional 124,586 shares in the last quarter. State Street Corp increased its holdings in shares of Agios Pharmaceuticals by 37.4% during the fourth quarter. State Street Corp now owns 3,108,145 shares of the biopharmaceutical company’s stock worth $84,604,000 after buying an additional 845,433 shares in the last quarter. Erste Asset Management GmbH increased its holdings in shares of Agios Pharmaceuticals by 1.4% during the fourth quarter. Erste Asset Management GmbH now owns 2,804,900 shares of the biopharmaceutical company’s stock worth $76,343,000 after buying an additional 40,000 shares in the last quarter. Finally, Commodore Capital LP lifted its stake in shares of Agios Pharmaceuticals by 6.4% in the 2nd quarter. Commodore Capital LP now owns 2,325,000 shares of the biopharmaceutical company’s stock valued at $77,330,000 after acquiring an additional 140,000 shares during the last quarter.

Agios Pharmaceuticals Stock Down 0.1%

NASDAQ AGIO opened at $33.60 on Friday. The company has a market capitalization of $2.01 billion, a price-to-earnings ratio of -4.79 and a beta of 0.60. Agios Pharmaceuticals, Inc. has a twelve month low of $22.24 and a twelve month high of $46.00. The stock has a fifty day simple moving average of $35.26 and a 200 day simple moving average of $32.03.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its earnings results on Thursday, July 30th. The biopharmaceutical company reported ($1.69) EPS for the quarter, missing the consensus estimate of ($1.65) by ($0.04). Agios Pharmaceuticals had a negative return on equity of 35.67% and a negative net margin of 418.24%.The company had revenue of $44.75 million for the quarter, compared to analyst estimates of $26.39 million. Research analysts expect that Agios Pharmaceuticals, Inc. will post -5.82 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms recently weighed in on AGIO. Weiss Ratings reissued a “sell (d)” rating on shares of Agios Pharmaceuticals in a report on Wednesday, June 24th. Citigroup upped their target price on Agios Pharmaceuticals from $46.00 to $52.00 and gave the stock a “buy” rating in a report on Friday, July 31st. Truist Financial dropped their target price on Agios Pharmaceuticals from $41.00 to $39.00 and set a “buy” rating for the company in a research report on Friday, July 31st. Royal Bank Of Canada lifted their price target on Agios Pharmaceuticals from $28.00 to $32.00 and gave the company a “sector perform” rating in a research note on Tuesday, July 7th. Finally, JPMorgan Chase & Co. boosted their price target on Agios Pharmaceuticals from $31.00 to $34.00 and gave the stock a “neutral” rating in a report on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Agios Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $41.25.

Insider Activity

In other news, insider Sarah Gheuens sold 30,000 shares of the firm’s stock in a transaction dated Tuesday, August 4th. The stock was sold at an average price of $30.48, for a total transaction of $914,400.00. Following the completion of the transaction, the insider directly owned 54,645 shares in the company, valued at $1,665,579.60. This trade represents a 35.44% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.40% of the stock is owned by company insiders.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.